Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Cloverleaf Bio raises $33 million in Seed financing to advance RNA-based cancer therapeutics, led by 4BIO Capital with participation from AbbVie Ventures and others.

PRIVATESep 08, 2026•about 3 hours ago

Amount Raised

$33 Million

Round Type

Seed

New HavenBiotechnologyHealth CareMedicalTherapeutics

Investors

American Cancer Society Bright EdgeMission Bio CapitalDraper AssociatesBoehringer Ingelheim Venture FundEli Lilly And CompanyAbb Vie Ventures4 Bio Capital

Description

Cloverleaf Bio has successfully closed a $33 million Seed financing round to support the development of its RNA-based cancer therapies. The round was led by 4BIO Capital and included significant investments from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund. These funds will help advance two lead programs targeting hepatocellular carcinoma and colorectal cancer. The strong participation from pharmaceutical investors underscores interest in Cloverleaf's scientific platform.

Company Information

Company

Cloverleaf Bio

Location

New Haven, Connecticut, United States

About

Cloverleaf Bio is an RNA therapeutics company focused on developing a new class of engineered transfer RNA (tRNA) based payloads for cancer treatment. Their platform is designed to inhibit multiple RNA-modifying enzymes that cancer cells depend on for proliferation. The company is advancing two lead programs targeting hepatocellular carcinoma and colorectal cancer. Cloverleaf aims to bring innovative cancer treatments from the lab to clinical settings.

Don't miss Cloverleaf Bio's next move

Get an email the moment Cloverleaf Bio raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Cloverleaf Bio's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Cloverleaf Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.